Alzheimer’s, Parkinson’s Drugs May Be M&A Targets, Huang Says

Treatments for neurodegenerative diseases could emerge as the next hot spot in health-care mergers and acquisitions, Morgan Stanley’s head of M&A for the Americas said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.